<DOC>
	<DOCNO>NCT00228059</DOCNO>
	<brief_summary>This extension study design investigate long-term safety tolerability licarbazepine 750-2000 mg/day 52 week patient complete 3-week double-blind study CLIC477D2301 .</brief_summary>
	<brief_title>An Open-label Extension Study Evaluate Safety Tolerability Licarbazepine Treatment Manic Episodes Bipolar I Disorder .</brief_title>
	<detailed_description>A 52-week , open-label extension study evaluate safety tolerability licarbazepine 750- 2000 mg/day treatment manic episode bipolar I disorder</detailed_description>
	<mesh_term>Disease</mesh_term>
	<criteria>1. write informed consent provide prior participation extension study 2. successful completion study CLIC477D2301 3. willingness ability comply study requirement 1. premature discontinuation study CLIC477D2301 2. failure comply study CLIC477D2301 protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bipolar disorder , manic episode/treatment/licarbazepine</keyword>
</DOC>